Stay updated on CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial
Sign up to get notified when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.

Latest updates to the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAdded B-cell chronic lymphocytic leukemia to the study's listed conditions. This expands the potential disease scope for inclusion.SummaryDifference0.0%

- Check33 days agoChange DetectedRevision tag updated from v3.4.3 to v3.5.0 on the page. This update does not affect the study details, eligibility, or other user-facing content.SummaryDifference0.0%

- Check40 days agoChange DetectedPage revision updated to v3.4.3 on 2026-03-12 with new entries (126, 2026-03-11, 2026-03-09). The previous revision v3.4.2 (2026-02-14, 2025-07-25, 130) has been superseded.SummaryDifference0.3%

- Check62 days agoChange DetectedEnrollment updated to 130 (from 126). The latest update dates are Last Update Posted on 2026-02-17 and Last Update Submitted on 2026-02-14, with earlier dates removed.SummaryDifference0.2%

- Check69 days agoChange DetectedRevision: v3.4.2 is now displayed; the notice about government funding lapse and the Revision: v3.4.1 update have been removed.SummaryDifference0.3%

Stay in the know with updates to CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD19/CD22 CAR T Cells in Pediatric B Cell Malignancies Clinical Trial page.